FDA Intelligence | FDA

Advertising and Promotion

Oct 13, 2022
How Will FDA’s Approach to COVID-19 Vaccines and Treatments Affect Future Promotion Enforcement?
Sep 12, 2022
How Will Push for Real-World Data and Evidence Change Marketing?
Jul 25, 2022
FDA, FTC Eyeing Celebrity Endorsements
Jul 13, 2022
Push for Switches to OTC May Change Drug Advertising Landscape
Jun 7, 2022
Overused Terms in Ads Are Losing Their Meaning
May 5, 2022
Common Violation Themes Emerge from Recent OPDP Enforcement Letters
Apr 15, 2022
Patient Influencers Could Be the Next Frontier in DTC Drug Marketing
Apr 7, 2022
Ad Promo Rules for Accelerated Approval Products May Be Changing
Feb 25, 2022
What’s Ahead for Ad Promo Policies Under FDA Commissioner Robert Califf?
Feb 9, 2022
First 2022 Untitled Letter Indicates OPDP’s Ongoing Concerns and Priorities

Good Clinical Practice

Food Labeling

FDA Regulation & Enforcement

Medical Devices

Copyright © Thompson FDA, a division of CBIS. All rights reserved.